You can thank Cowen for that.
In a note out this morning, investment banker Cowen initiated coverage of Rockley stock with an outperform rating and a $22 price target that implies the stock will more than double over the next year.
“RKLY’s silicon photonics sensing platform addresses a well over $48B” total addressable market, explained Cowen in its note, covered today on StreetInsider.com. “We expect strong initial adoption by leading consumer wearable device companies focused on expanding and enhancing health and wellness applications followed by eventual penetration of the medical device market.”
Until that penetration happens, however, Rockley Photonics remains an iffy investment. Valued in excess of $1.1 billion, and with $162 million in net debt besides, Rockley did less than $12 million in sales over the past year — and is far from a profitable operation. (In fact, the company lost $149 million and burned through $94 million in negative free cash flow.)
It’s difficult to value a stock like this one. On the one hand, Cowen could be right about the company’s potential, and Rockley could grow quickly, leading to rapid gains in stock price. On the other hand, it hasn’t done this yet — and indeed to the contrary, sales at Rockley so far this year are down nearly more than 70% from last year’s first half.
The analyst’s optimism notwithstanding, I’d classify Rockley stock as an extremely speculative idea.
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.